 AstraZeneca PLC LSE:AZN is set to pay out US775mln to settle a patent dispute between its recently acquired rare diseases business Alexion and the Chugai Pharmaceutical Company. The litigation relates to a drug called Ultomiris, used to treat paroxysmal nocturnal hemoglobinuria and atypical haemolytic uraemic syndrome two life-threatening conditions. 